An Investigation of Saliva and Plasma Levels of Urotensin-2 in Recently Diagnosed Type 2 Diabetes Mellitus Patients on Metformin Treatment
Open accessAbstract
INTRODUCTION: Diabetes mellitus (DM) is a primary disease of the carbohydrate metabolism that is characterised by absolute or relative insulin deficiency, or insulin resistance. Although life expectancy is low for diabetic patients, the prognosis has been improved in recent decades. Metformin is an oral antidiabetic that reduces insulin resistance and plasma glucose levels by decreasing glucose production in the liver. It can be used as a standalone treatment or in combination with other antidiabetic medications or insulin. Urotensin 2 (U-II), which is one of the most effective known vasoconstrictor peptides, was observed to act as a vasoconstrictor in diseases such as hypertension and heart failure, and to induce vasodilation in healthy volunteers. Some studies have proposed that the activation of the U-II system could lead to metabolic syndrome. Certain studies have determined a link between DM and U-II. However, there exist no studies on the effects of U-II in recently diagnosed type 2 DM patients after metformin treatment. This study aims to investigate the plasma and saliva levels of U-II at diagnosis and after a three-month metformin treatment in recently diagnosed type 2 DM patients, and to compare these levels to those of healthy volunteers. MATERIAL AND METHODS: Our study compared 30 recently diagnosed type 2 DM patients to their states after three-month metformin treatment and 30 healthy volunteers. RESULTS: When compared with the control group, there was no significant increase in the plasma and saliva U-II levels of recently diagnosed type 2 DM patients. We determined a statistically significant increase in the plasma and saliva ureotensin-2 levels of recently diagnosed type 2 DM patients after a three-month metformin treatment (p < 0.05). CONCLUSIONS: It was concluded that the patients with type 2 DM have a multifactorial aetiopathogenesis and an increase in U-II levels after metformin treatment. Metformin has no known effect on the U-II metabolism; therefore, the findings need confirmation through more clinical and experimental studies with more participants.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
de Luise, M. (1993) · Medical Journal of Australia · doi:10.1097/00007611-200295010-00001 · Cited by 5,074 · cited 1×
“Type 2 diabetes mellitus (DM) is a primary disorder of the carbohydrate mechanism, which has chronic progression, a multifactorial aetiopathogenesis, is characterised by absolute or relative insulin deficiency or insulin resistance, presents with high plasma glucose levels as the primary symptom, demonstrates signific…”
BackgroundRole of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441 · see citing works
Joslin, E., & Marble, A. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-5-820_3 · Cited by 1,049 · cited 1× · see citing works
“Besides its acute complications, DM progresses with chronic complications such as retinopathy, which causes vision loss in the long term; nephropathy and vascular diseases, which cause renal failure; neuropathy, which ultimately results in the amputation of the foot; and additionally, with autonomous neuropathy, which…”
BackgroundAydin, S. (2015) · Peptides · doi:10.1016/j.peptides.2015.04.012 · Cited by 626 · cited 1× · see citing works
“The measurement of U-II in saliva samples by the U-II kit was assessed according to the procedure published by Aydin, and the kit was determined to measure U-II in saliva samples as well [16].”
MethodEl‐Remessy, A. B., Behzadian, M. A., Abou-Mohamed, G., Franklin, T., Caldwell, R. W., & Caldwell, R. B. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64332-5 · Cited by 203 · see citing works
Djordjevic, T., BelAiba, R. S., Bonello, S., Pfeilschifter, J. M., Hess, J., & Görlach, A. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000154279.98244.eb · Cited by 164 · see citing works
Increased plasma urotensin II levels in patients with diabetes mellitus
Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Ito, S., & Murakami, O. (2003) · Clinical Science · doi:10.1042/cs20020271 · Cited by 160 · cited 1× · see citing works
“Urine and plasma U-II levels of type 2 diabetic patients were found to be higher in those with disrupted renal function than in those with normal renal function [10].”
BackgroundBousette, N., Patel, L., Douglas, S. A., et al. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.03.023 · Cited by 137
Urotensin II: Its Function in Health and Its Role in Disease
Kwok, L.-O., Lam, K., & Cheung, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-6899-x · Cited by 108
Anushiravani, A., Haddadi, N., Pourfarmanbar, M., & Mohammadkarimi, V. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001369 · Cited by 107 · cited 1× · see citing works
“[22], which included 150 patients, no statistically significant differences were found between the metformin group and the placebo group in terms”
BackgroundVaudry, H., Leprince, J., Chatenet, D., Fournier, A., Lambert, D. G., Mével, J. L., Ohlstein, E. H., Schwertani, A. G., Tostivint, H., & Vaudry, D. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009480 · Cited by 104 · see citing works
Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy.
Langham, R., Kelly, D., Gow, R., et al. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.07.021 · Cited by 102 · cited 1×
“Tubular epithelial cells obtained from the nephrectomy of patients with diabetic nephropathy showed an overexpression of U-II and the urotensin receptor [11].”
BackgroundTotsune, K., Takahashi, K., Arihara, Z., et al. (2004) · Peptides · doi:10.1016/j.peptides.2004.06.024 · Cited by 102 · cited 1×
“[24], which included 48 patients diagnosed with type 2 DM and 10 healthy volunteers, the patients were assigned to three groups based on their renal function tests.”
MethodRole of urotensin II and its receptor in health and disease
McDonald, J., Batuwangala, M., & Lambert, D. (2007) · Journal of Anesthesia · doi:10.1007/s00540-007-0524-z · Cited by 56
Suguro, T., Watanabe, T., Kodate, S., Xu, G., Hirano, T., Adachi, M., & Miyazaki, A. (2008) · Clinical Science · doi:10.1042/cs20080014 · Cited by 41 · cited 1× · see citing works
“Recent studies have demonstrated that U-II can be used as a biomarker in type 2 DM patients with diabetic nephropathy and atherosclerosis and rheumatic valvular disease [15].”
BackgroundImportance of Postprandial Glucose Levels as a Target for Glycemic Control in Type 2 Diabetes
Tibaldi, J. M. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e318188898e · Cited by 39 · see citing works
Sidharta, P., Rave, K., Heinemann, L., et al. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03480.x · Cited by 31 · cited 1× · see citing works
“[29], the urotensin receptor antagonist palosuran was administered to type 2 DM patients, who were followed-up with dietary guidance for four weeks, and they determined no changes in insulin secretion, insulin sensitivity, and daily blood glucose levels when compared to the placebo group.”
MethodGruson, D., Rousseau, M. F., Ketelslegers, J., et al. (2010) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00336.x · Cited by 29 · cited 2×
“[28] included 360 patients diagnosed with type 2 DM, 294 patients diagnosed with metabolic syndrome, and 66 patients without metabolic syndrome, in different groups.”
BackgroundUrotensin-II level and its association with oxidative stress in early diabetic nephropathy.
Tabur, S., Korkmaz, H., Eren, M. A., et al. (2015) · Journal of diabetes and its complications · doi:10.1016/j.jdiacomp.2014.07.011 · Cited by 25 · cited 2×
“The authors [27] reasoned, based on these findings, that the U-II molecule could be involved in the development of diabetic nephropathy.”
BackgroundShaker, M. (2010) · Oman Medical Journal · doi:10.5001/omj.2010.84 · Cited by 21 · cited 1× · see citing works
“In a study that included 60 patients diagnosed with polycystic ovary [23], Shaker et al.”
BackgroundÇalan, M., Arkan, T., Küme, T., & Bayraktar, F. (2018) · HORMONES · doi:10.1007/s42000-018-0084-7 · Cited by 12 · see citing works
Liver enzyme trends in patients taking uninterrupted metformin before and after coronary surgery
Nazer, R. I., Abalhassan, M. F., & Alburikan, K. A. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.05.04 · Cited by 5 · cited 1× · see citing works
“[21] compared patients on metformin to those who were not, in terms of their alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and total bilirubin levels before and after a coronary artery bypass graft, and determined a significant decrease in those who used metformin.”
BackgroundPlasma Urotensin II Concentration In Gestational Diabetes
Huristoglu, M., Ekiz, A., Mete, F., Okuturlar, Y., Koçoğlu, H., Dumanlı, G. Y., Çakırca, M., Anataca, G., Kuru, O., Doğan, S., et al. (2017) · ARCHIVES OF CLINICAL AND EXPERIMENTAL MEDICINE · doi:10.25000/acem.336837 · Cited by 1 · cited 1× · see citing works
“[26] compared 21 women diagnosed with gestational DM, 15 pregnant women without a DM diagnosis, and 22 age-matched, non-pregnant women.”
Flagged first, then by citations
Research works printed but not linked: 3
- Ong KL, Lam KSL, Cheung BMY. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther. 2005; 19(1): 65–75.
- McDonald J, Batuwangala M, Lambert DG. Role of urotensin II and its receptor in health and disease. J Anesth. 2007; 21(3): 378–389.
- Ong KL, Lam KSL, Cheung BMY. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther. 2005; 19(1): 65–75.
Cited by
Sorted by citations
Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions
de Oliveira dos Santos, A. R., de Oliveira Zanuso, B., Miola, V. F. B., Barbalho, S. M., Santos Bueno, P. C., Flato, U. A. P., Detregiachi, C. R. P., Buchaim, D. V., Buchaim, R. L., Tofano, R. J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052639 · Cited by 189 · see citing works
Shabir, K., Brown, J. E. P., Afzal, I., Gharanei, S., Weickert, M. O., Barber, T. M., Kyrou, I., & Randeva, H. S. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.05.002 · Cited by 61 · see citing works
Fibrillin-1 and asprosin, novel players in metabolic syndrome
SUMMERS, K. M., Bush, S. J., Davis, M. R., et al. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.106979 · Cited by 24 · see citing works
Urotensin-II As a Promising Key-Point of Cardiovascular Disturbances Sequel
Avagimyan, A. A., Albina, K., Gabunia, L., et al. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101074 · Cited by 14 · see citing works
Vastrad, B. M., & Vastrad, C. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.16.537071 · Cited by 1 · see citing works
Hipercalcemia Moderada Secundario a Adenoma Paratiroideo Intratiroideo: Reporte de Caso
de León, M. A. V., Díaz, L. A. H., Huerta, N. V. M., et al. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i2.10801
- Authors
- GOZEL, N., Oral, K., Ozdemir, F. A., Onalan, E., Kuloglu, T., Aydın, S., Karataş, A., & Kılınç, F.
- Affiliations
- Fırat University (TR)
- Venue
- Endokrynologia Polska
- Publisher
- VM Media SP. zo.o VM Group SK
- Published
- 2020-04-07
- Volume
- 71
- Issue
- 3
- Pages
- 249-255
- ISSN
- 0423-104X (ISSN-L)
- 2299-8306
- OpenAlex
- W3015724214
- Cited by
- 6
- References
- 23
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 1 · 2021: 3
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Endokrynologia Polska (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DSpace - FIRAT (Fırat University) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- type 2 diabetes, metformin, salivary biomarkers, plasma biomarkers, newly diagnosed diabetes, vasoconstrictor peptides, insulin resistance, metabolic syndrome
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Saliva, Urotensins, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
